= Abstract = Cytomegalovirus (CMV) is currently the most common agent of congenital infection and the leading infectious cause of brain damage and hearing loss in children. Symptomatic congenital CMV infections usually result from maternal primary infection during early pregnancy. One half of symptomatic infants have cytomegalic inclusion disease (CID), which is characterized by involvement of multiple organs, in particular, the reticuloendothelial and central nervous system (CNS). Moreover, such involvement may or may not include ocular and auditory damage. Approximately 90% of infants with congenital infection are asymptomatic at birth. Preterm infants with perinatal CMV infection can have symptomatic diseases such as pneumonia, hepatitis, and thrombocytopenia. Microcephaly and abnormal neuroradiologic imaging are associated with a poor prognosis. Hearing loss may occur in both symptomatic and asymptomatic infants with congenital infection and may progress through childhood. Congenital infection is defined by the isolation of CMV from infants within the first 3 weeks of life. Ganciclovir therapy can be considered for infants with symptomatic congenital CMV infection involving the CNS. Pregnant women of seronegative state should be counseled on the importance of good hand washing and other control measures to prevent CMV infection. Heat treatment of infected breast milk at 72℃ for 5 seconds can eliminate CMV completely. (Korean J Pediatr 2010;53:14-20) 
Introduction
Human cytomegalovirus (CMV) is a member of the Herpesviridae family of DNA viruses and ubiquitous in the general population. Most CMV infections are inapparent, but the virus can cause a wide range of diseases in neonates and immunocompromised patients. CMV is the most common cause of congenital infection worldwide, affecting 0.2 % to 2.4% of all live births [1] [2] [3] [4] . CMV is now the most common viral cause of mental retardation and hearing deficit of children in developed countries [5] [6] [7] . CMV causes deformation of preformed tissues rather than malformation of developing organs 8) , so CMV can affect fetuses beyond the first trimester, although earlier infection is usually more severe [8] [9] [10] . Primary maternal infection is most likely to cause severe symptomatic congenital infection 11) , but recurrent infection may also rarely do so. Peri-natal CMV infection is usually not associated with clinical illness in term babies, but may also cause serious problems in preterm infants [12] [13] [14] [15] .
Transmission
Transmission of CMV occurs from person to person through body fluids, and requires close contact with contaminated secretions because the virus in not very contagious. CMV can be found in blood, urine, semen, cervical secretions, saliva, breast milk and transplanted organs, all these sites intermittently excrete viruses 1, 12) . Viral excretion is particularly prolonged after primary infection over years but also occurs with reactivation of infection 1, 5) .
Transmission of CMV to fetuses and newborn infants occurs in one of following modes 12, [15] [16] [17] [18] : (1) in utero by transplacental passage from hematogenous spread to the fetus during maternal viremia; (2) at birth by intrapartum passage after exposure to infected cervical and vaginal secretions; (3) postnatally by ingestion of CMV-positive breast milk or infected blood transfusion. The rate of symptomatic infection at birth is less than 1%. The suggested incidence rate reflects data reported in the pediatric literature 1-6, 8, 9) .
Epidemiology
CMV infection is endemic and lacking in seasonal variation. Congenital CMV infection can result from maternal primary or reactivated infection during pregnancy 1, 5) . And also maternal reinfection of different strains of CMV can rarely lead to congenital symptomatic infection 19, 20) . The prevalence of congenital CMV infection varies between 0.2-2.4% in different countries [1] [2] [3] [4] . In developed countries, around 50-60% of pregnant, middle to high class women have antibodies to CMV, compared with around 70-85% of those from lower socioeconomic groups 3, 4) . Overall, 1-4% of susceptible women are affected with primary CMV infection during pregnancy, and around 30-40% of the fetus are transplacentally infected, and also about 10% infants manifest clinical signs and symptoms at birth [1] [2] [3] [4] [5] . Approximately 1-3% of infants born of women with preexisting antibody to CMV are infected in utero, but they have rarely symptomatic illnesses at birth (less than 1%) 5, 19) . It has been known that the risk of symptomatic infections at birth or the baby who will develop subsequent sequelae is higher if maternal infection occurs during the first half of pregnancy, and also most of severe congenital infection is caused by primary rather than recurrent infection of pregnant women 5, 10, 11) . A suggested schema of congenital CMV infection and its outcome may be a possible scenario in the community (Fig. 1) .
Perinatal CMV infection can result from exposure to infected secretions of maternal genital tract at delivery or breast milk that contains the virus. Around 2-28% of seropositive mothers shed CMV in cervical and vaginal secretions during delivery, and approximately 50% of exposed infants are infected 15) . Around 9-88% of seropositive women shed CMV into their milk, and approximately 50-60% of infants fed breast milk that contains the virus become infected 15, 21) . Transfusion-acquired perinatal CMV infection occurs in infants of seronegative mothers who are exposed to blood products that contain the virus. The incidence of infection is about 10-30% and occurs usually preterm infants with a birth weight of less than 1,500 g 1, 22) . The risk of infection is related the volume of transfused blood or number of donors, and the titer of CMV in donor blood 15) .
Clinical manifestation 1. Congenital infection
Approximately 10% of infants with congenital CMV infection have signs and symptoms at birth, and only one half of these babies have the fulminant illness; cytomegalic inclusion disease (CID) 13, 15) . Another 5% of these infants show mild and atypical involvement, and 90% are born with 15) subclinical but chronic infection 2, 15) . The symptomatic infection of infants usually results from primary infection of the mother 5, 9) . And it appear that the risk is greater, the earlier in gestation the infection occurs 5, 11) .
Infants with CID typically have a purpuric rash due to thrombocytopenia (usually with petechiae), intrauterine growth retardation (IUGR), hepatosplenomegaly, jaundice, hearing loss, microcephaly, chorioretinitis and intracerebral calcification. More commonly, infected infants may exhibit a wide spectrum of disease with only one or a few of these manifestations 15) (Table 1) . Premature infants or babies who are small for gestational age with hepatosplenomegaly and abnormal liver function are most common findings of symptomatic congenital CMV infection 4) . Hyperbilirubinemia may be transient with a rise in the direct component. Thrombocytopenia is developed one third of infants with congenital infection, and may persist for weeks 5) . There may also be a Coombs-negative hemolytic anemia 5, 11) . Pneumonia may develop as a late findings of congenital CMV infection, usually occurring at 1-4 months of age 1, 15) . CMV pneumonia in preterm infants has been associated with development or exacerbation of bronchopulmonary dyslasia (BPD) 23) . And also postnatal administration of steroid for BPD in CMV-infected perterm infants has been associated with progression of CMV disease 15) .
A major important issue in congenital CMV infection is cental nervous system (CNS) involvement including meningoencephalitis, calcification, microcephaly, disturbance of neuronal migration, germinal matrix cysts, ventriculomegaly and cerebellar hypoplasia 6) . 8, 24, 25) . Hearing loss apparently result from viral replication in the inner ear 26) .
Infants with symptomatic congenital CMV infection have a mortality rate of 20-30% 4, 9) . Death are usually due to hepatic dysfunction, bleeding, disseminated intravascular coagulopathy or secondary bacterial infection 4) .
Perinatal infection
The incubation period of perinatal CMV infection ranges between 4 and 12 weeks (mean, 8 weeks) 1, 15) . The quan- .
Transfusion-acquired CMV infection in preterm babies
with very low birth weight may develop severe symptoms .
Diagnosis
Congenital CMV infection is diagnosed by isolation of virus from infants within the first 3 weeks of life 3, 13, 15) . So it is difficult to differentiate whether CMV infection was acquired congenitally or perinatally in infants more than 3 weeks of age, unless clinical features of the former such as chorioretinitis, intracranial calcification, microcephaly and hearing loss, are present 13, 15) .
CMV is usually isolated from urine and saliva but may be isolated other body fluids including breast milk, cervicovaginal secretions, amniotic fluid, white blood cell, cerebrospinal fluid, stool and biopsy specimens. The best test for diagnosis of congenital or perinatal CMV infection is virus isolation or demonstration of CMV genetic material by polymerase chain reaction (PCR) from urine or saliva of newborn infants 1, 15) . The sensitivity of PCR with urine specimens is 89%, and the specificity is 96% 1, 27) . Urine specimens should be refrigerated (4℃) but never frozen or stored at room temperature. The recovery rate of viruses remains at 93% in urine after 7 days of refrigeration, decreasing to 50% after 1 month 5) . Although a fourfold rise in IgG titer in paired sera or a strong positive IgM anti-CMV may be a useful finding suggesting infection, serologic assays are not recommended for diagnosis of CMV infection in neonates. Because IgG anti-CMV detected in newborn infants reflects transplacentally acquired maternal antibody and that can persist for up to 18 months of age 15) . And also IgM assay has both false positive and false negative 28, 29) .
Computed tomography (CT) is most sensitive to detect .
Treatment
There are now two drugs for systemic treatment of congenital and perinatal CMV infection: ganciclovir and valganciclovir (oral prodrug of ganciclovir).
In a randomized controlled, multicenter, phase III study with ganciclovir (6 mg/kg/dose intravenously every 12 hr for a 6 week course) 30) , it was carried out to treat newborn infants who have congenital CMV infection involving the CNS, as defined by microcephaly, intracranial calcification, abnormal findings of cerebrospinal fluid, chorioretinitis and/ or hearing deficit. When tested at 6 months, 84% of treated infants maintained normal hearing or improved their hearing, in contrast to 59% of control infants. At 6 months followup, none of the treated infants had hearing deterioration, while 41% of control patients did. When tested 1 year of age or beyond 21% of treated and 68% of control infants had hearing deterioration. Primary ganciclovir-related toxicity was neutropenia. 63% of treated infants developed neutropenia, compared with 21% of control infants.
In a pharmacokinetic and pharmacodynamic study of oral valgancyclovir in treatment of infants with congenital CMV infection 31) , it showed that a 6 mg/kg intravenous ganciclovir dose and 16 mg/kg oral valganciclovir provides similar systemic exposure to ganciclovir. In addition, treated patients with a 6 week course decreased in viral load of 0.7 log viral DNA copies/mL in urine. Toxicity of valganciclovir is similar to that of ganciclovir with 38% of subjects developing neutropenia.
Treatment with ganciclovir of a 6 week course can be considered for symptomatic infants with congenital CMV infection involving the CNS, but can not be routinely recommended 15) . A 2 week course of ganciclovir may be beneficial in critically ill infants with symptomatic perinatal CMV infection. And additional 1-2 weeks of ganciclovir can be considered if symptoms and signs have not been resolved 12) .
Prognosis
Infection during early pregnancy more often result in more severe sequelae than infection later in pregnancy.
Approximately 50-90% of symptomatic survivors have long-term sequelae such as microcephaly, hearing loss, motor deficit (paresis/paralysis), cerebral palsy, mental retardation, seizure, ocular abnormalities (chorioretinitis, optic atrophy), autism and learning disabilities 32) (Table 2 ).
In contrast, 10-15% of infant with congenital CMV infection who are asymptomatic at birth have long-term neurodevelopmental injury.
Factors associated with poor cognitive prognosis are microcephaly and abnormalities detected on brain CT 4, 6) .
In contrast, children with normal findings on brain CT and normal head circumference have been revealed to have a good cognitive outcome 33) . So radiologic findings of brain with MRI and CT may be the most specific and sensitive predictors of neurodevelopmental outcomes 6) . Microcephaly dose not always persist, and dose not always result in later handicap. Infants who have microcephaly alone without other neurologic findings have relatively a good prognosis in early childhood 34) . Chorioretinitis is nearly always indicative significant mental retardation and often lead to optic atrophy. It can also develop on several weeks after birth 8) .
SNHD, the most common sequelae of congenital CMV infection may occur in both symptomatic and asymptomatic infected infants. Although about 60% of infants with hearing loss is developed at birth or in neonatal period, at least 40 % may have delayed-onset loss 6) . Additionally progression of hearing loss in patients who had already SNHD has also been observed in about 60% of infants with through childhood and into adolescence 15, 25, 35) . So all babies with congenital CMV infection should be followed at least school entry, and hearing test regularly performed to detect late deficit 6, 8) . Patient with disseminated symptomatic infection including petechiae or IUGR at birth and those with higher viral load at birth appear to have an increased risk of hearing loss 1, 35) .
Premature and ill full-term infants with serious perinatal CMV infection may be an increased risk of neurologic sequlae and psychomotor retardation, even though there dose not appear to be a higher rate of SNHD, microcephaly and chorioretinitis 1, 2) .
Prevention
CMV is usually not very contagious, and its horizontal transmission requires direct contact with infected materials, such as different secretions that contain the virus, and less likely, formites. So adherence to standard precautions with good hand hygiene is effective to prevent CMV infection 1, 13) .
Preexisting maternal immunity to CMV affords significant protection to the fetus. In contrast, with maternal primary infection, the overall risk for delivering a symptomatic neonate is about 5% 3, 4, 9) . So women of childbearing age should have CMV serologic tests, especially if they provide care for young children who are potential CMV excreters 1, 2, 36) . And pregnant women who are CMV seronegative should be provided with information on prevention measures and reassured that common sense steps such as hand washing and avoiding contact with secretions should prevent this infection 1, 37) . Although newborn hearing screening programs may miss the late-onset hearing loss complicated in congenital CMV infection, routine screening of all newborns for CMV is not yet recommended 38, 39) . Pasteurization (72℃ for 5 seconds) of breast milk can inactivate CMV completely without affecting nutritional and immunologic properties of milk, although freezing (-20℃ for 3-7 days) will significantly decrease viral titers 12, 40, 41) . Transfusion-acquired CMV infection is eliminated by administration of CMV antibody-negative blood products and filtration of blood to remove white blood cells 12) .
CMV vaccine ultimately may be an important preventive measure, but are not yet successful.
